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Obscurin and KCTD6 regulate cullin-dependent 
small ankyrin-1 (sAnk1.5) protein turnover
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aSchool of Medicine, University of California, San Diego, La Jolla, CA 92093-0613; bRandall Division for Cell and 
Molecular Biophysics and Cardiovascular Division, King’s College London BHF Centre of Research Excellence, London 
SE1 1UL, United Kingdom
ABSTRACT Protein turnover through cullin-3 is tightly regulated by posttranslational modifi-
cations, the COP9 signalosome, and BTB/POZ-domain proteins that link cullin-3 to specific 
substrates for ubiquitylation. In this paper, we report how potassium channel tetramerization 
domain containing 6 (KCTD6) represents a novel substrate adaptor for cullin-3, effectively 
regulating protein levels of the muscle small ankyrin-1 isoform 5 (sAnk1.5). Binding of sAnk1.5 
to KCTD6, and its subsequent turnover is regulated through posttranslational modification 
by nedd8, ubiquitin, and acetylation of C-terminal lysine residues. The presence of the 
sAnk1.5 binding partner obscurin, and mutation of lysine residues increased sAnk1.5 protein 
levels, as did knockdown of KCTD6 in cardiomyocytes. Obscurin knockout muscle displayed 
reduced sAnk1.5 levels and mislocalization of the sAnk1.5/KCTD6 complex. Scaffolding func-
tions of obscurin may therefore prevent activation of the cullin-mediated protein degradation 
machinery and ubiquitylation of sAnk1.5 through sequestration of sAnk1.5/KCTD6 at the 
sarcomeric M-band, away from the Z-disk–associated cullin-3. The interaction of KCTD6 with 
ankyrin-1 may have implications beyond muscle for hereditary spherocytosis, as KCTD6 is 
also present in erythrocytes, and erythrocyte ankyrin isoforms contain its mapped minimal 
binding site.
INTRODUCTION
The exact mechanism underlying the simultaneous degradation and 
synthesis of myofibrils in actively working myocytes remains a mys-
tery in muscle biology. Muscle cells contain up to four proteolytic 
systems that enable them to achieve coordinated protein turnover 
(Martinez-Vicente et al., 2005; Su and Wang, 2010): the caspase and 
calpain systems of partially muscle-specific proteases; the ubiquitin 
proteasome system (UPS), which degrades polyubiquitylated pro-
teins via the 26S proteasome; and the autophagy system, which re-
moves proteins by inclusion in autophagic/lysosomal vesicles. These 
systems do not necessarily operate in isolation, as there is increasing 
evidence of cross-talk between autophagy and the UPS (Bjorkoy 
et al., 2009). The UPS consists of two parts: an enzymatic cascade 
attaching ubiquitin to substrates intended for degradation and the 
proteasome complex, which facilitates proteolytic cleavage of poly-
ubiquitylated substrates. Specific substrate recognition is achieved 
by dedicated ubiquitin E3 ligases. More than 100 such E3-enzymes 
are described, some of which (e.g., the muscle-specific ring-finger 
[MuRF] family) are specific for striated muscle. Cullin proteins are 
another set of ubiquitin E3 ligases that are ubiquitously expressed. 
In contrast to other E3 ligases, cullins do not bind their substrate 
directly, but rely on an array of adaptor proteins, such as the muscle-
specific atrogin-1 (MAFbx/FBXO32; Gomes et al., 2001). Besides 
F-box–containing proteins, substrate adaptors containing BTB/POZ 
domains are also considered another class of linker proteins.
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channel tetramerization domain containing 6 (KCTD6). We charac-
terize the biological functions of KCTD6 as a specific linker for cullin-
3–dependent protein turnover, as well as its oligomerization and 
interaction with sAnk1.5.
The presence of the KCTD6 binding site in erythrocyte isoforms 
of ankyrin-1 and detection of KCTD6 in purified red blood cells indi-
cate that this interaction may have implications beyond striated 
muscles. Indeed, pathological mutations that result in truncated 
ankyrin-1 lacking the KCTD6 binding site may suggest a role for this 
complex in the development of hereditary spherocytosis.
RESULTS
sAnk1.5 interacts with KCTD6 in striated muscle
In search for interaction partners for the muscle-specific isoform 
sAnk1.5 of ankyrin 1, we performed a yeast two-hybrid screen using 
a human cardiac cDNA library as bait and the cytoplasmic part of 
sAnk1.5 as prey. Out of 30 clones, four correctly identified the ob-
scurin C-terminus as an sAnk1.5 binding partner, indicating the suc-
cessful implementation of the screening method. Eight clones en-
coded for the N-terminus of KCTD6, a novel interaction partner for 
sAnk1.5 (Table 1). Verification of the interaction by forced yeast two-
hybrid assays (Figure 1A) and coimmunoprecipitations (Figure 1C) 
indicated that the minimal binding sites for the interaction reside in 
the N-terminal BTB/POZ domain of KCTD6 (Figure 1D), as well as 
within a region of sAnk1.5 encompassing the obscurin binding do-
main 2 (OBD-2; Figure 1B). Failure to demonstrate binding using 
bacterially expressed glutathione S-transferase (GST)-tagged ankyrin 
(residues 29–155) in pulldowns (Supplemental Figure S1A) or full-
length KCTD6 derived from nonmyogenic cells (Figure 1C) sug-
gested that the interaction is dependent on tissue-specific post-
translational modifications of ankyrin and/or KCTD6.
We reported previously that ankyrin undergoes posttranslational 
modification by ubiquitin and/or nedd8 (Lange et al., 2009). How-
ever, Lys-R mutants that lack the modification of sAnk1.5 by ubiquitin-
like modifiers (Lange et al., 2009), as well as Cys/Gly mutants that 
cannot form ankyrin dimers via cysteine bridges (Porter et al., 2005), 
retain their ability to interact with KCTD6 (Figure S1C), suggesting 
another form of posttranslational modification necessary for the 
KCTD6/sAnk1.5 complex formation. To identify whether phosphory-
lation of sAnk1.5 or KCTD6 triggers the interaction, we performed 
mutational analysis of serine or threonine residues in sAnk1.5 and 
One recently described BTB/POZ domain–containing protein 
family that may act as cullin-3 substrate linkers are the KCTD pro-
teins. KCTD proteins were named after their N-terminal BTB/POZ 
domain, which has high homology with tetramerization domains 
of potassium channels. Among the 22 KCTD proteins in humans, 
KCTD5 (Bayon et al., 2008), KCTD13/BACURD1, as well as 
KCTD13’s paralogue TNFAIP1 (BACURD2; Chen et al., 2009) have 
been demonstrated to interact directly with cullin-3 and mediate 
substrate recognition for subsequent ubiquitylation. Specific sub-
strates for the KCTD–cullin complex include the small GTPase 
RhoA (Chen et al., 2009) and, putatively, the Golgi-associated 
GRASP55 (Dementieva et al., 2009).
It is documented that muscle-specific E3 ligases can bind to sar-
comeric proteins such as titin (Spencer et al., 2000; Centner et al., 
2001; McElhinny et al., 2002; Witt et al., 2005; Mrosek et al., 2007; 
Muller et al., 2007) and participate in sarcomerogenesis and myofi-
brillar maintenance (Lange et al., 2005b; Perera et al., 2011). Con-
versely, it is yet to be determined whether ubiquitous E3 ligases, 
such as cullin proteins could also have important roles in muscle 
development and function. Intriguingly, cardiac-specific ablation of 
CSN8, a COP9-signalosome subunit involved in the regulation of 
cullin activity, leads to a dilated cardiomyopathy phenotype (Su 
et al., 2010), while cullin-7/p193 overexpression improves cardiac 
function (Nakajima et al., 2004; Hassink et al., 2009). Moreover, the 
strong sarcomeric association of the cullin-1 substrate linker atrogin-1 
with components of the sarcomeric Z-disk (Li et al., 2004) and the 
M-band association of CSN5 in Caenorhabditis elegans muscle 
(Miller et al., 2009) highlight the importance of this class of E3 li-
gases for striated muscles.
Like titin, members of the obscurin protein family are thought to 
be important for sarcomere assembly and maintenance. Composed 
mainly of immunoglobulin-like and fibronectin type-III domains, the 
obscurin protein family consists of three members: obscurin (Bang 
et al., 2001; Young et al., 2001), obscurin-like 1 (Obsl1; Geisler et al., 
2007; Fukuzawa et al., 2008), and striated muscle preferentially ex-
pressed protein kinase (SPEG/APEG; Hsieh et al., 2000; Liu et al., 
2009). In contrast to Obsl1, obscurin and SPEG/APEG contain ad-
ditional protein kinase domains, RhoGEF domains, or an IQ-motif, 
hinting at a role for both proteins in muscle-specific signaling (Young 
et al., 2001; Bowman et al., 2008; Ford-Speelman et al., 2009). One 
of the best-characterized functions of the obscurin-A C-terminus is 
its interaction with small ankyrin-1 isoform 5 (sAnk1.5; Bagnato 
et al., 2003; Kontrogianni-Konstantopoulos et al., 2003). This mus-
cle-specific isoform of ankyrin-1 lacks all characteristic domains as-
sociated with ankyrin proteins: N-terminal ankyrin repeats, a spec-
trin-binding domain, and the C-terminal death domain, but includes 
in its N-terminus a unique transmembrane domain that integrates 
into the sarcoplasmic reticulum (SR) of cross-striated muscle cells 
(Gallagher and Forget, 1998; Porter et al., 2005). We previously 
showed that ablation of obscurin leads to reduction of sAnk1.5 pro-
tein levels, its mislocalization to the sarcomeric Z-disk/I-band region, 
and dramatically altered SR architecture (Lange et al., 2009).
More recently it has emerged that mammalian obscurin proteins 
or the C. elegans homologue UNC-89 associate either indirectly 
(Hanson et al., 2009; Huber et al., 2009) or directly (Litterman et al., 
2011; G. Benian, personal communication) with cullins, and putatively 
regulate cullin-mediated protein turnover (Miller et al., 2006, 2009).
In this study, we set out to further investigate why sAnk1.5 pro-
tein levels were reduced in muscles of obscurin knockout animals by 
studying novel sAnk1.5 interactions. We show that sAnk1.5 turnover 
is regulated by posttranslational modification, presence of obscurin, 
and tissue-specific interaction with a novel partner—potassium 
Clone number NCBI accession number Protein
1 NM_052843.2 Obscurin
3 NM_153331 KCTD6
5 NM_153331 KCTD6
12 NM_153331 KCTD6
16 NM_153331 KCTD6
17 NM_052843.2 Obscurin
19 NM_153331 KCTD6
20 NM_153331 KCTD6
21 NM_153331 KCTD6
23 NM_052843.2 Obscurin
24 NM_153331 KCTD6
26 NM_052843.2 Obscurin
TABLE 1: sAnk1.5 cytoplasmic part yeast two-hybrid results.
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and sAnk1.5 in transfected Cos-1 cells (Fig-
ure S1D) further supports binding within 
cells. KCTD21, which is the closest paralogue 
to KCTD6 (Bayon et al., 2008), and KCTD5 
demonstrated no interaction with sAnk1.5, 
highlighting the specificity of the ankyrin–
KCTD6 interaction (unpublished 
observations).
Binding of sAnk1.5 to KCTD6 is 
promoted by acetylation
Recently, KCTD6 has been implicated in his-
tone deacetylase (HDAC) signaling and 
deacetylase turnover (De Smaele et al., 
2011). We investigated whether acetylation 
of sAnk1.5 may promote interaction of full-
length KCTD6 with sAnk1.5 in nonmuscle 
cells. Treatment of Cos-1 cells with HDAC-
inhibitor TSA allowed binding of sAnk1.5 to 
KCTD6, whereas KCTD6 assayed from un-
treated Cos-1 cells showed no interaction 
(Figure 2B). Moreover, immunoprecipitation 
of proteins containing acetylated lysine resi-
dues suggested acetylation of sAnk1.5 in 
trichostatin A (TSA)-treated Cos-1 cells, as 
compared with lower levels of acetylated 
sAnk1.5 from untreated cells (Figure 2F, left 
side of right panel). In comparison, full-
length KCTD6 showed no appreciable lysine 
acetylation, even upon TSA treatment of 
Cos-1 cells (Figure S2A, right panel), sug-
gesting that acetylation of sAnk1.5 may trig-
ger binding of the two proteins. To identify 
acetylated regions within sAnk1.5, we trans-
fected Cos-1 cells with either full-length 
sAnk1.5, or C-terminal truncation constructs 
expressing residues 1–137, 1–99, 1–63, and 
a mutated 1–63 sAnk1.5 version that re-
places lysine residues 38 and 46 with argin-
ine (Figure 2F, right side of right panel). High 
levels of acetylated ankyrin were observed 
with the full-length sAnk1.5, whereas trun-
cation of sAnk1.5 C-terminus to residue 137 
or 99 resulted in decreased or abrogated acetylation of the protein, 
respectively. We then investigated whether increased binding of 
acetylated sAnk1.5 to KCTD6 can be automatically correlated with 
increased sAnk1.5 protein turnover. Surprisingly, HDAC inhibition 
by TSA did not alter protein turnover of sAnk1.5 in transfected Cos-1 
cells (Figure S2B), indicating that ubiquitylation by E3 ligases and/or 
degradation of ubiquitylated proteins by the proteasome may be 
further regulated by other cofactors. Taken together, these results 
indicate that acetylation of the sAnk1.5 C-terminal lysine residues 
(Figure 3F) may promote interaction with KCTD6. Increased binding 
of sAnk1.5 to KCTD6, however, does not automatically correlate 
with increased sAnk1.5 protein turnover.
KCTD6 and sAnk1.5 associate with ubiquitin 
and ubiquitin-like modifiers
Ankyrins are subjected to the E3-ligase activity of spectrins, their 
interaction partners (Chang et al., 2004; Hsu and Goodman, 2005). 
We previously demonstrated that sAnk1.5 is modified by ubiquitin 
and nedd8 (Lange et al., 2009), however, it lacks all the necessary 
KCTD6. Mutation of Ser-113, Ser-114, and Ser-129 in sAnk1.5 to ei-
ther alanine or aspartic acid did not alter the interaction of sAnk1.5 
with KCTD6 (Figure 2A), nor did mutation of Ser-130, Ser-155, Ser-
214, or Thr-199 in KCTD6 (unpublished observations). Moreover, 
staurosporine and/or phosphatase treatment of KCTD6 and sAnk1.5 
from C2C12 cells did not inhibit binding (Figure S1B). Therefore 
phosphorylation of sAnk1.5 and/or KCTD6 in the investigated resi-
dues does not trigger their interaction. Intriguingly, mutation of Lys-
101 in sAnk1.5’s obscurin binding domain 2 (OBD-2) to glutamic 
acid, which completely abrogates obscurin binding (Borzok et al., 
2007), could decrease, but not inhibit, formation of the KCTD6/
sAnk1.5 complex (Figure 2, A and B). The intact interaction of KCTD6 
with the Lys-101E sAnk1.5 mutant indicates further that sAnk1.5 may 
bind obscurin and KCTD6 simultaneously. Indeed, the localization of 
KCTD6 and sAnk1.5 at the level of the sarcomeric M-band in heart 
and skeletal muscle (Figure 2, C–E) supports the formation of a ter-
nary obscurin–sAnk1.5–KCTD6 complex, as does coimmunoprecipi-
tation of KCTD6 N-terminus (1–147) with sAnk1.5 and the obscurin-A 
C-terminus (Figure S1C). Colocalization of KCTD6 N-terminus (1–147) 
FIGURE 1: sAnk1.5 interacts with KCTD6 in a tissue-specific manner. (A) Forced yeast two-
hybrid identified a region including OBD-2 as minimal binding site for KCTD6. Yeast transformed 
with either empty pACT2 vector or pACT2-KCTD6 (residues 1–147) together with pLexA-
sAnk1.5 constructs expressing small ankyrin regions 29–155, 29–137, 29–99, or 29–63 were 
grown on SD-LW minimal medium (left). Xgal filter assay (right) indicated a region within 
sAnk1.5 residues 100–137 as a minimal binding site for sAnk1.5 interaction with KCTD6. 
(B) Schematic representation of sAnk1.5 domain structure and mapped KCTD6 minimal-binding 
site. TM, transmembrane domain; OBD, obscurin binding domain. All residues are for human 
sAnk1.5 (NCBI accession number: NP_065211). (C) Coimmunoprecipitation of either full-length 
GFP-tagged KCTD6, KCTD6 N-terminus (residues 1–147), or C-terminus (residues 105–237) with 
HA-tagged sAnk1.5 using cell lysates from transfected Cos-1 or differentiated C2C12 cells (day 
7). Full-length KCTD6 displays binding to sAnk1.5 only in lysates from differentiated C2C12 
cells, whereas proteins isolated from transfected Cos-1 cells demonstrated only interaction of 
KCTD6 N-terminus with sAnk1.5. I, input; UB, unbound; B, bound fractions. (D) Schematic 
representation of KCTD6 domain structure and minimal sAnk1.5 binding site. The minimal 
binding site to sAnk1.5 encompasses the N-terminal BTB/POZ domain in KCTD6. Results for 
GST-pulldown assays (Figure S1A), coimmunoprecipitations from transfected Cos-1 or C2C12 
cell lysates (C) demonstrate the muscle-specific interaction of sAnk1.5 with full-length KCTD6. 
All residues are for human KCTD6 (NCBI accession number: NP_699162).
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binding sites for spectrin proteins. Because 
neddylation of a substrate protein has been 
reported to enhance its subsequent ubiqui-
tylation (Pan et al., 2004; Oved et al., 2006), 
we investigated the temporal order and 
spatial relationship between sAnk1.5 and 
nedd8 or ubiquitin. Using the protein com-
plementation assay (split–fluorescent pro-
tein system), we observed that in the ab-
sence of the proteasome inhibitor MG132, 
only sAnk1.5 modified by nedd8 can be de-
tected (Figure 3A). Detectable association 
of sAnk1.5 with ubiquitin could only be 
demonstrated after treatment of cells with 
MG132 (Figure 3B). These results indicate 
that ubiquitylated sAnk1.5 is too short-lived 
to allow detectable complementation of the 
fluorescent protein, whereas neddylated 
sAnk1.5 appears more stable, as evidenced 
by readily observable yellow fluorescent 
protein (YFP) fluorescence (Figure 3A, top 
panel). Sumo1, another ubiquitin-like modi-
fier, demonstrated no association with 
sAnk1.5 (Figure S2C). These results are con-
gruent with previous data, confirming that 
neddylated sAnk1.5 exhibits lower molecu-
lar weights compared with polyubiquity-
lated sAnk1.5 and that sAnk1.5 is not su-
moylated (Lange et al., 2009).
To investigate which lysine residues in 
sAnk1.5 allow attachment of ubiquitin, we 
investigated the rate of sAnk1.5 protein 
degradation using the ribosome inhibitor 
cycloheximide (CHX). We determined that 
sAnk1.5 half-life in transfected Cos-1 cells 
is ∼6 h (Figure 3D, black bars), which is 
comparable with the turnover of endoge-
nous sAnk1.5 measured in differentiated 
C2C12 cells (Figure 3C). Using wild-type 
sAnk1.5 and Lys-38R, Lys-46R, Lys-73R, 
Lys-105R, and Lys-38/73R sAnk1.5 mu-
tants (Figure 3, D–F), we could demon-
strate that sAnk1.5 mutated at lysine resi-
dues Lys-38 and K73 exhibits significantly 
increased protein levels after 6 h of CHX 
treatment, indicating impairment of 
sAnk1.5 turnover in these mutants. We 
also studied whether the presence of the 
obscurin-A C-terminus exerts an influence 
on sAnk1.5 turnover, but found no notice-
able difference (Figure 3E, black bars). 
Analysis of Lys-38R, Lys-73R, Lys-105R, 
and Lys-38/73R mutants, however, showed 
significantly increased sAnk1.5 levels when 
coexpressed with obscurin. Specifically, 
the decreased protein turnover for the 
Lys-38R mutant coexpressed with obscu-
rin indicates that some lysine residues lo-
cated in OBD-1 and -2 of ankyrin may be 
engaged in binding obscurin and are 
therefore inaccessible for ubiquitylation.
FIGURE 2: Posttranslational modification of sAnk1.5 affects its interaction with KCTD6. 
(A) Mutational analysis of putative serine phosphorylation sites and conserved lysine in 
minimal KCTD6 binding site of sAnk1.5 (residues 100–137). Coimmunoprecipitation of 
transfected Cos-1 cells expressing GFP-tagged KCTD6 N-terminus with either HA-tagged 
sAnk1.5 wild-type, Ser-113A, Ser-129A, Ser-113/114A, Ser-113/129A, Ser-113/114/129A, or 
Lys-101E (Borzok et al., 2007) mutants displayed weaker, but not abrogated, binding of 
KCTD6 to sAnk1.5 Ser-101E mutant. Full-length KCTD6 shows no binding to sAnk1.5 in 
Cos-1 cells. (B) HDAC inhibition by TSA triggers binding of sAnk1.5 with full-length KCTD6 
in nonmuscle cells. Binding of wild-type and mutant sAnk1.5 (Lys-101E, Glu-121K) to either 
full-length of C-terminally truncated KCTD6 (residues 1–147) from Cos-1 cells was assessed 
in absence or presence of 0.5 μg/ml TSA. Mutation of either Lys-101E or Glu-121K did not 
alter interaction of sAnk1.5 to C-terminally truncated KCTD6. Full-length KCTD6 isolated 
from COS-1 cells only interacted with sAnk1.5 after incubation of cells with TSA. 
(C to E) Subcellular localization of endogenous sAnk1.5 (C), KCTD6 (D and E) in heart (C and 
D) or skeletal muscle cells (E) shows that both proteins localize at the M-band in wild-type 
cross-striated muscles. (C to E) Scale bar: 10 μm. (F) Acetylation of sAnk1.5 C-terminus. 
Inhibition of HDAC by TSA leads to increased acetylation of sAnk1.5 as demonstrated by 
coimmunoprecipitation using an acetyl-lysine antibody (K-Ac; right). Truncation of the 
sAnk1.5 C-terminus decreases (residues 1–137) or abolishes acetylation (residues 1–63; 
residues 1–63 Lys-38/46R double mutant).
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Ankyrin has been shown to form oligo-
meric complexes (Porter et al., 2005), pre-
sumably through disulfide bridges at the 
Cys-22/Cys-34 residues. Analysis of the 
sAnk1.5 secondary structure (Figure S2D) 
indicated the presence of a helical region in 
the cytoplasmic part of sAnk1.5 (residues 
29–47) immediately following the helical 
transmembrane domain. Intriguingly, resi-
dues Leu-33, Leu-37, Ile-40, and Leu-44 
form a hydrophobic pocket in the pinwheel 
view (Figure S2F), which may help to pro-
mote ankyrin oligomerization. To investigate 
whether oligomerization of sAnk1.5 may 
play a role in its turnover, we assessed the 
cysteine–glycine mutant Cys-22G/Cys-34G, 
the Leu-44R mutant, and the Cys-22G/Cys-
34G/Leu-44R triple mutant. Comparison of 
wild-type sAnk1.5 after 6 h of CHX treat-
ment with either of these mutants showed 
that abrogation of disulfide-bridge forma-
tion resulted in increased protein turnover, 
whereas additional mutation of Leu-44R in 
the Cys-22G/Cys-34G/Leu-44R mutant sig-
nificantly decreased sAnk1.5 protein degra-
dation (Figure S2E).
FIGURE 3: sAnk1.5 is modified by nedd8 and ubiquitin. Identification of lysine residues 
important for protein turnover. (A) Protein complementation assay using YFP (split–fluorescent 
protein assay) demonstrated neddylation of sAnk1.5 in Cos-1 cells. Cos-1 cells transfected with 
N-terminal YFP-tagged (YN; Zou et al., 2006) nedd8 and C-terminal YFP-tagged (YC) sAnk1.5 
(bottom, GFP antibody staining red in overlay) display close association/modification of sAnk1.5 
by nedd8 as evidenced by complementation of YFP and restoration of endogenous fluorescence 
(top). Note that the putative neddylation of sAnk1.5 is readily visible without MG132 treatment. 
(B) Protein complementation assay as in (A) using YN-ubiquitin and sAnk1.5-YC demonstrated 
visible modification of sAnk1.5 by ubiquitin only in MG132 treated Cos-1 cells (top). Untreated 
Cos-1 cells show no detectable ubiquitylation of sAnk1.5, despite expression of constructs 
(bottom, GFP-antibody red in overlay, DAPI blue in overlay). Scale bar: 20 μm. (C) Analysis of 
endogenous sAnk1.5 protein degradation in differentiated C2C12 cells using ribosome inhibitor 
CHX, shows an apparent protein half-life of ∼5 h, comparable with transfected sAnk1.5 in Cos-1 
cells (see D). Loading control: β-tubulin. (D) CHX treatment of COS-1 cells transfected with 
wild-type or mutant sAnk1.5 indicates Lys-38 and Lys-73 as important for ubiquitylation/
degradation. Cos-1 cells transfected with HA-tagged wild-type, Lys-38R, Lys-46R, Lys-73R, 
Lys-105R or Lys-38/73R sAnk1.5 were treated with 10 μg/ml CHX for 6 h. Densitometric 
quantification of wild-type sAnk1.5 levels indicated a protein half-life of ∼6 h (black bars). 
Comparison of lysine mutants with the wild-type protein after 6 h of CHX treatment displayed a 
slight increase of sAnk1.5 for Lys-38R and 
Lys-73R mutants. The Lys-38/73R double 
mutant showed significantly increased 
protein amount (white bar), when compared 
with wild-type sAnk1.5 after 6 h of treatment. 
(E) Presence of obscurin C-terminus 
influences sAnk1.5 degradation. Cos-1 cells 
transfected with wild-type, Lys-38R, Lys-46R, 
Lys-73R, Lys-105R or Lys-38/73R sAnk1.5 with 
or without obscurin C-terminus 
encompassing the ankyrin binding site 
(Bagnato et al., 2003; Kontrogianni-
Konstantopoulos et al., 2003) were treated 
with CHX for 6 h. Whereas wild-type sAnk1.5 
showed no change in its degradation with or 
without coexpression of obscurin (black bars), 
Lys-38R, Lys-73R, Lys-105R and Lys-38/73R 
mutants show significantly increased sAnk1.5 
levels after 6 h of CHX treatment, when 
coexpressed with obscurin. Similarity of 
Lys-38R mutant sAnk1.5 levels in presence of 
obscurin, with amounts of sAnk1.5 Lys-
38/73R double mutant (in D) indicate that 
either Lys-73R mutation, or binding of Lys-73 
with obscurin are beneficial for sAnk1.5 
protein half-life. (D and E) p values, n values 
(bottom of each graph), and SEM are 
displayed. (F) Representation of sAnk1.5 
domain layout and posttranslational 
modification by ubiquitin, nedd8, and 
acetylation. Lysines in sAnk1.5 and regions 
responsible for posttranslational modification 
are indicated (dark shaded = high likelihood 
of modification). Lysines mutated for protein 
turnover investigations displayed in bigger 
letters. Arrows indicate residues influencing 
turnover.
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emerged that two KCTD family members, 
KCTD5 and KCTD13 (BACURD1), interact 
with and may be targets of cullin-3 (Bayon 
et al., 2008; Chen et al., 2009). We therefore 
asked whether association of KCTD proteins 
with cullin-3 is a general hallmark of this pro-
tein family, and whether KCTD6 is a putative 
binding partner of cullin-3.
Coimmunoprecipitation assays con-
firmed that KCTD6 interacts with the un-
structured cullin-3 N-terminus (Figure 4, A 
and B), as recently reported (De Smaele 
et al., 2011). This feature is reminiscent of 
the interaction of KCTD5 with cullin-3, 
whereby the BTB domain of KCTD5 also in-
teracts with the N-terminal half of cullin-3 
(Bayon et al., 2008). However, in contrast 
with sAnk1.5 (Lange et al., 2009), KCTD6 
did not undergo neddylation (Figure S3A). 
Next we analyzed whether sAnk1.5 itself is 
associated with cullin-3. Coimmunoprecipi-
tation of sAnk1.5 with cullin-3 demonstrates 
a linkage between the two proteins (Figure 
4, C and D) putatively mediated by endog-
enous KCTD proteins. Intriguingly, only full-
length, but not modified or truncated, 
sAnk1.5 (Figure 4C) could be precipitated 
by cullin-3.
Endogenous cullin-3 in cardiomyocytes 
and skeletal muscle cells localizes at the 
sarcomeric Z-disk (Figure 4, E and F). How-
ever, since cullin action is enzymatic, minute 
levels of cullin-3 should be sufficient to me-
diate ubiquitylation of target proteins out-
side the Z-disk region. Additionally, we ob-
served that cullin-3 colocalizes with KCTD6 
(Figure S3, B, D, and E), and sAnk1.5 in 
Cos-1 cells (Figure S3C).
KCTD6 is up-regulated during muscle development
Nedd8 was reported to be down-regulated during embryonic de-
velopment (Kamitani et al., 1997). To gain insight into the precise 
spatial and temporal expression of nedd8, KCTD6, cullin, and COP9 
signalosome–associated proteins, and their relevance for muscle 
development and function, we studied their expression levels and 
localization in various tissues during development.
KCTD6 is expressed in a broad range of tissues. The highest ex-
pression was found in the liver, for which a 30-kDa band was ob-
served (Figure 5A, top KCTD6 panel). Heart, kidney, and smooth 
muscle (stomach) displayed a 25-kDa immunopositive band, indi-
cating two distinct KCTD6 moieties. Longer exposure revealed the 
30-kDa band to be almost ubiquitous (Figure 5A, bottom KCTD6 
panel). Cullin-3 (Figure 5A) and nedd8 (Figure S4A) were also de-
tected in all investigated tissues. To address whether cullin-medi-
ated protein turnover was important for sarcomerogenesis, we ex-
plored the expression profile of KCTD6, cullin-3, the cullin-associated 
protein Skp1, and CSN5 as a representative of the COP9 signalo-
some during postnatal heart growth and C2C12 differentiation.
Expression levels of KCTD6 and sAnk1.5 increased during post-
natal heart development and C2C12 myotube formation (Figure 5, 
B and C), comparable with the developmental regulation of Skp1 
and sarcomeric myosin (Figures 5C and S4B). Up-regulation of 
In summary, we observed that sAnk1.5 protein turnover depends 
on the availability of Lys-38 and Lys-73 for ubiquitylation (Figure 3F, 
big arrows), the presence of the ankyrin binding partner obscurin, 
and the oligomerization state of the protein.
We also considered whether KCTD6 is involved in the neddyla-
tion/ubiquitylation process of its interaction partner sAnk1.5, and 
whether KCTD6 itself may be subject to neddylation/ubiquitylation 
by using the protein complementation assay. Although KCTD6 is 
found in proximity to nedd8 within cells (Figure S2G), it is not post-
translationally altered by ubiquitin or ubiquitin-like modifiers in 
baseline conditions, as evidenced by the absence of higher-molec-
ular-weight bands representing modified KCTD6 in immunoblots 
(Figure S3A). Similar to sAnk1.5, KCTD6 is only associated with 
ubiquitin after MG132 treatment (Figure S2H), and not with Sumo1 
(Figure S2I). These data indicate a role for KCTD6 in neddylation 
and ubiquitylation of substrate proteins such as sAnk1.5, without 
KCTD6 itself being subjected to modification by nedd8.
KCTD6 mediates sAnk1.5 association to cullin-3
BTB/POZ domain–containing proteins act as scaffolding/adaptor 
proteins in a variety of complexes. A prominent example is the cul-
lin-3 E3 ligase that requires BTB/POZ domain–containing proteins 
to link it to its substrates (Bosu and Kipreos, 2008). It has recently 
FIGURE 4: Association of sAnk1.5 and KCTD6 with E3 ligase cullin-3. (A) KCTD6 associates with 
the unstructured cullin-3 N-terminus. Coimmunoprecipitation of HA-tagged KCTD6 with 
GFP-tagged full-length cullin-3, cullin-3 N-terminus (residues 1–384), or cullin-3 C-terminus 
(residues 384–768) shows binding of KCTD6 to the N-terminal region of cullin-3. (B) Schematic 
representation of cullin-3 domain structure and minimal KCTD6 binding site as determined in 
(A). Cullin ligase domain and Nedd8 modification site in cullin-3 are indicated. Residue numbers 
according to human cullin-3 (NCBI accession number: NP_003581). (C) Coimmunoprecipitation 
of full-length or sAnk1.5 N-terminus (residues 1–63) demonstrates association of cullin-3 with 
full-length unmodified sAnk1.5, but not of the sAnk1.5 N-terminus. (A and C) I, input; UB, 
unbound; B, bound fractions. (D) Schematic representation of ankyrin domain structure and 
protein region required for association of sAnk1.5 with cullin-3, as demonstrated in (C). 
(E and F) Immunofluorescence of cardiac (E) and skeletal muscle (F, Dia) display localization of 
cullin-3 to the sarcomeric Z-disk (arrowheads) as validated by colocalization with sarcomeric 
α-actinin. Scale bar: 6 μm.
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sAnk1.5, KCTD6 and cullin-3 was also mir-
rored in immunofluorescence images of un-
differentiated and differentiated C2C12 
cells (Figure 5D). Analysis of the subcellular 
localization revealed that differentiating 
myoblasts display elevated cullin-3 in a ve-
sicular pattern at day 0 and more diffusely at 
day 7 (Figure 5D, arrowhead in day 0, arrow 
in day 7 cullin-3 panel, respectively). The ex-
pression level of CSN5, a component of the 
COP9 signalosome that regulates cullin E3-
ligase activity, remained comparable with 
undifferentiated myoblasts (Figure S4B).
In summary, KCTD6, sAnk1.5, cullin-3, 
and their associated proteins are expressed 
in muscle and developmentally up-regu-
lated during sarcomerogenesis.
KCTD6 forms parallel homomeric 
complexes
Named for their tetramerization domain 
(BTB/POZ domain), which is homologous to 
homomeric interaction domains of potas-
sium channels, KCTD proteins are thought 
to form tetramers. However, the crystal 
structure of KCTD5 yielded a surprising 
pentameric conformation (Dementieva 
et al., 2009) despite being characterized 
earlier as a tetramer in biochemical experi-
ments (Bayon et al., 2008).
To understand KCTD6 binding, we in-
vestigated whether KCTD6 forms parallel or 
antiparallel complexes, and whether the 
KCTD6 C-terminus exhibits a conforma-
tional shape that could effectively block in-
teraction with sAnk1.5 in nonmyogenic 
cells. Data from the protein complementa-
tion assay confirmed that KCTD6 forms par-
allel protein complexes in cells, bringing 
the N-termini of the individual KCTD6 pro-
teins in close spatial vicinity (Figure S5A). 
We also found that KCTD6 is not assuming 
FIGURE 5: Analysis of KCTD6 developmental and tissue-specific expression pattern. 
(A) Analysis of endogenous KCTD6 and cullin-3 protein levels in various mouse tissues. High 
levels of KCTD6 were found in heart (H), kidney (Ki), liver (Li), and stomach (St; top, KCTD6 blot). 
Ubiquitous low expression was also found in all other analyzed tissues, namely skeletal muscle 
(Sk), lung (Lu), brain (Br), uterus (Ut), ovaries (Ov), and testes (Te). Note that the KCTD6 antibody 
cross-reacts with bands at approximately 30 kDa and 25 kDa, with 30 kDa representing 
full-length KCTD6. Cullin-3 was found to be ubiquitously expressed throughout all analyzed 
tissue samples (middle). GAPDH was used as loading control (bottom). Asterisk indicates that 
the liver sample was diluted 1/10 for the KCTD6 blot. (B) Immunoblots of KCTD6 and sAnk1.5 
expression in cardiac muscle at P0, P20, and adult stages indicates up-regulation of both 
proteins during postnatal development. (C) Analysis of sAnk1.5, KCTD6, cullin-3, sarcomeric 
myosin heavy chain (MyHC), and GAPDH protein levels during C2C12 differentiation. sAnk1.5 
and KCTD6 display increased protein levels 
during C2C12 myotube development, as 
judged by expression of sarcomeric marker 
protein MyHC, while cullin-3 remains largely 
unchanged from undifferentiated myoblast 
stage (day 0). Note that the larger band in 
cullin-3 may represent nedd8-modified 
cullin-3. (D) Analysis of sAnk1.5, KCTD6, 
cullin-3, and obscurin protein localization in 
undifferentiated C2C12 myoblasts (day 0) 
and differentiated C2C12 myotubes. Note 
that despite overall down-regulation of 
cullin-3 levels in C2C12 cells (see C), cullin-3 
expression levels appear higher in 
differentiated C2C12 cells (arrowhead in 
cullin-3 Day 0), when compared with 
neighboring undifferentiated cells (arrow in 
cullin-3 bottom). DAPI blue in overlay; 
sarcomeric marker α-actinin red in overlay. 
Scale bar: 20 μm.
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a conformational “U” shape that would bring the KCTD6 N-termi-
nus and C-terminus into proximity, thereby putatively blocking 
sAnk1.5 binding to the full-length KCTD6 BTB/POZ domain (Figure 
S5B). Using chemical cross-linking of full-length and C-terminally 
truncated KCTD6, we also analyzed whether KCTD6 forms tetra-
meric or pentameric complexes in cells. Full-length KCTD6 forms 
mainly dimeric and tetrameric complexes, as well as higher-order 
products (Figure S5C, left panel). No pentameric assemblies could 
be identified. C-terminally truncated KCTD6 is only able to form 
dimeric complexes in chemical cross-linking experiments (Figure 
S5C, right panel). As shown previously, the truncated dimeric form 
of KCTD6 BTB domain is able to interact with sAnk1.5 in nonmyo-
genic cells (Figure 1C). Taken together, these data indicate that the 
KCTD6 C-terminus may play important roles for complete tetramer-
ization, and its ability to interact with other binding partners.
Analysis of KCTD6 interaction with its closest paralogue KCTD21 
(Bayon et al., 2008) and the well-characterized KCTD5 indicated ab-
sence of heteromer formation in either scenario (Figure S5D). These 
results agree with recent data on KCTD6 heteromerization (De 
Smaele et al., 2011).
In summary, KCTD6 forms parallel homo-tetramers, with its 
N-terminal BTB/POZ domain being important for initial dimer for-
mation, and its C-terminus being important for complete tetramer-
ization/oligomerization and regulation of its interaction with cullin-3 
substrate proteins.
KCTD6 regulates sAnk1.5 protein levels
Our results indicate that KCTD6 in combination with obscurin and 
cullin-3 may be important for small ankyrin protein turnover. Intrigu-
ingly, the degradation of RhoA, another protein that binds to the 
C-terminus of obscurin (Ford-Speelman et al., 2009), is also depen-
dent on cullin-3 and its interaction with another member of the 
KCTD protein family, KCTD13 (BACURD1; Chen et al., 2009). Using 
RNA interference (RNAi), we investigated whether KCTD6 is neces-
sary for sarcomerogenesis and protein turnover of the putative cul-
lin-3 substrates sAnk1.5, as well as KCTD13- and obscurin-associated 
RhoA in neonatal rat cardiomyocytes (NRC).
Knockdown of KCTD6 in NRC resulted in significantly lowered 
KCTD6 protein levels of cells transfected with H1-rtKCTD6-green 
fluorescent protein (GFP; Figure 6A, top panels), whereas KCTD6 
levels in untransfected or H1-GFP–transfected control cells remained 
unchanged (Figure 6A, bottom panel). RhoA displayed no changes 
in protein level or subcellular localization (Figure 6A, RhoA panels). 
Knockdown of KCTD6, however, dramatically increased sAnk1.5 
protein levels (Figure 6B, top panel). Conversely, overexpression of 
KCTD6 was associated with a significant decrease of sAnk1.5 levels 
(Figure S6A). Sarcomerogenesis and myofibrillar maintenance were 
unaffected by KCTD6 knockdown, as judged by undisturbed α-
actinin and obscurin staining (Figures 6B and S6B). Taken together, 
these data indicate that sAnk1.5 protein levels are inversely corre-
lated to KCTD6 expression, and support the notion that sAnk1.5 
protein turnover may be regulated by the UPS (Figure S6C) and cul-
lin-3 substrate-linker functions of KCTD6.
Obscurin knockout animals exhibit changes in cullin 
and COP9 signalosome–associated proteins
We recently reported that skeletal muscles of obscurin knockout ani-
mals exhibit an abnormal SR architecture and develop a mild myo-
pathy. A major hallmark in these mice was the altered localization 
and expression of sAnk1.5, which was found to be regulated on the 
protein, but not the mRNA, level (Lange et al., 2009). Because 
knockdown of KCTD6 in cardiomyocytes was associated with 
up-regulation of sAnk1.5 protein levels, we wondered whether ob-
scurin may exert an influence on cullin-3 and KCTD6. Several recent 
reports indicate that obscurin/UNC-89 and its close homologue 
Obsl1 are directly or indirectly linked to cullin E3 ligases (Benian, 
personal communication; Hanson et al., 2009, 2011; Huber et al., 
2009; Litterman et al., 2011).
To further examine the influence of obscurin on cullin, we inves-
tigated expression levels and localizations of sAnk1.5, KCTD6, cul-
lin-3, and RhoA, in the obscurin knockout mice. All investigated 
proteins exhibited distinctive changes in localization in hearts of ob-
scurin knockout animals (Figure 7A). Specifically, RhoA was entirely 
diffuse, and the M-band localization of KCTD6 was significantly di-
minished. Moreover, KCTD6 and cullin-3 displayed a marked in-
crease in their association with the intercalated disk of obscurin 
knockout cardiomyocytes (Figure 7B). In contrast, expression levels 
of KCTD6 and cullin-3 remained mostly unaltered (Figure S7A). No-
table, however, is the increase in p62/sequestosome-1 expression in 
heart and skeletal muscle of obscurin knockouts, indicating putative 
alterations to general protein turnover, ubiquitin signaling, and/or 
autophagy (Figure S7A, p62 panel).
DISCUSSION
The regulated turnover of proteins is fundamental for cell function. 
Deregulation of protein degradation is associated with develop-
mental defects, impaired muscle differentiation, and embryonic le-
thality (Yue et al., 2003; Witt et al., 2008; Zhang et al., 2009; Jang 
et al., 2011). Proteins degraded by the UPS usually require polyu-
biquitylation by dedicated E3 ligases. For cullin-RING E3 ligases, 
substrate recognition and specificity are achieved through adaptor 
proteins, whereby each cullin has its own unique subset of linker 
protein families (Bosu and Kipreos, 2008): for example, cullin-3 de-
pends on BTB/POZ domain–containing proteins for substrate rec-
ognition, whereas cullin-1 relies on Fbox domain–containing pro-
teins, such as the muscle-specific FBXO32 (atrogin-1).
We identified KCTD6 as a novel binding partner of the muscle-
specific ankyrin isoform sAnk1.5 (Figure 8A). Localization of sAnk1.5 
and KCTD6 at the sarcomeric M-band in wild-type muscle, and the 
formation of a ternary KCTD6/sAnk1.5/obscurin complex in coim-
munoprecipitation experiments (Figure S1C) further indicate that 
sAnk1.5 binding to KCTD6 may occur alongside its interaction with 
obscurin. The minimal binding side for KCTD6 could be located 
along the concave surface of the obscurin binding domain 2 (OBD-2) 
in sAnk1.5, facing away from the loop regions of the ankyrin-like re-
peats that form the interaction side with obscurin (Borzok et al., 2007; 
Busby et al., 2011). Another hypothesis for the simultaneous binding 
of KCTD6 and obscurin to sAnk1.5 is based on the oligomerization of 
sAnk1.5 (Figure S2F), whereby one molecule in the sAnk1.5 oligomer 
interacts with obscurin, while another could bind KCTD6. However, 
coimmunoprecipitation experiments using the Cys-22G/Cys-34G/
Leu-44R/Gly/GlyR mutant sAnk1.5, which should prohibit sAnk1.5 
oligomer formation, indicated that one sAnk1.5 molecule is able to 
bind KCTD6 and the obscurin-A C-terminus simultaneously (Figure 
S1C). Future experiments that study cocrystallization structures or 
molecular modeling may resolve this question more thoroughly.
We further demonstrated that sAnk1.5 can be posttranslationally 
modified by ubiquitin, nedd8, and acetylation that may be respon-
sible for the muscle-specific interaction of sAnk1.5 with KCTD6. In 
contrast with a previous report indicating that neddylation of pro-
teins may promote their ubiquitylation and subsequent degrada-
tion (Oved et al., 2006), our protein complementation assays indi-
cated that neddylation was not associated with increased turnover 
of sAnk1.5, as evidenced by detectable neddylation of sAnk1.5 
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FIGURE 6: siRNA knockdown of KCTD6 in NRC. (A) siRNA-mediated knockdown of KCTD6 in NRC leads to reduced 
expression levels of endogenous KCTD6 when compared with either untransfected (KCTD6 RNAi; right panel, false-
color overlay with signal intensity as displayed), or H1-GFP transfected control cells (bottom right panel). (B) Knockdown 
of endogenous KCTD6 results in increased expression level of endogenous sAnk1.5 (top panel, KCTD6 RNAi), when 
compared with untransfected (top right panels, false-color overlay with signal intensity as displayed) or H1-GFP–
transfected control cells (bottom right panels). (A and B) Scale bar: 20 μm.
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Our binding assays and RNAi data and recent work done by oth-
ers (De Smaele et al., 2011) further indicate that KCTD6 may act as 
an sAnk1.5-specific substrate linker for cullin-3. The interaction of 
KCTD6 with cullin-3 and sAnk1.5 is dependent on its N-terminal 
BTB/POZ domain, which promotes dimerization of the protein. Fur-
ther tetramerization/oligomerization of KCTD6 was dependent on 
the unstructured KCTD6 C-terminus that may also be responsible 
for the recognition of acetylated sAnk1.5, thereby exerting the ob-
served tissue-specific binding of full-length KCTD6 to sAnk1.5.
Indeed, acetylation of proteins has been implicated as an avidity 
enhancer within interconnected multiprotein complexes (Scott et al., 
2011). Scott and colleagues describe how acetylation of an E2 ubiq-
uitin-conjugating enzyme leads to neddylation, and thereby activa-
tion of cullin-1. Our findings, whereby acetylation of the substrate 
(sAnk1.5) promotes binding of the adaptor protein (KCTD6), thereby 
putatively enabling the assembly of the protein complex with the E3 
ligase (cullin-3), fits this scheme. Although lysine acetylation of 
ankyrin 1 isoforms has been reported by tandem liquid chromatog-
raphy–tandem mass spectrometry experiments (Zhao et al., 2010), 
the biological function of acetylated ankyrin remains largely un-
known. Surprisingly, increased acetylation of sAnk1.5 was not asso-
ciated with increased sAnk1.5 turnover. While HDAC inhibition may 
exert side effects on components of the UPS on a global scale 
(Arendt and Hochstrasser, 1999), lysine acetylation has been shown 
to positively and negatively influence protein stability through differ-
ent mechanisms (for a review, see Caron et al., 2005). Future experi-
ments may elucidate whether acetylation of substrates, linker pro-
teins, and enzymes of the ubiquitin machinery acts as a general trig-
ger for activation of protein degradation through cullin proteins.
One of the key findings in our analysis of the obscurin knockout 
was the decreased level and altered localization of sAnk1.5 in mus-
cles of these mice (Lange et al., 2009). While we observed de-
creased sAnk1.5 protein, but not mRNA, in obscurin knockouts, the 
mechanism by which this occurred remained unclear. Using the 
knowledge that KCTD6 and cullin-3 may be involved in sAnk1.5 
turnover, we reexamined muscles from wild-type and obscurin 
knockouts. In wild-type, most of the KCTD6 staining colocalizes 
with sAnk1.5 and obscurin at the M-band, while cullin-3 resides ex-
clusively at the Z-disk (Figure 8B, left). This spatial separation of 
sAnk1.5/KCTD6 and cullin-3 appears drastically altered in obscurin 
knockout muscles, in which sAnk1.5, KCTD6, and cullin-3 colocalize 
at the Z-disk/I-band region (Figure 8B, right), bringing the substrate 
(sAnk1.5) and its specific linker (KCTD6) in close spatial contact with 
the E3 ligase (cullin-3). Moreover, increased association of KCTD6 
and cullin-3 at the intercalated disk in knockout hearts further sug-
gests that absence of obscurin may have implications for other hith-
erto unidentified KCTD6 binding partners and potential cullin-3 
substrates.
We also noted significant changes to p62/sequestosome-1 in 
obscurin knockouts. Because p62 is thought to link UPS-medi-
ated protein degradation with autophagy (Bjorkoy et al., 2009), 
alterations in p62 expression may indicate a general adaptation 
to protein turnover in obscurin knockout muscles. While the 
changed p62 expression levels and altered KCTD6 and cullin-3 
localization may represent secondary changes in response to ob-
scurin depletion, more direct links of obscurin family proteins 
with protein turnover have been observed. Direct association of 
the C. elegans obscurin homologue UNC-89 with cullin-1 (Benian, 
personal communication), and the interaction of the closely asso-
ciated Obsl1 with cullin-7 (Litterman et al., 2011) and its implica-
tion in the growth disorder 3-M syndrome (Hanson et al., 2009; 
Huber et al., 2009) may support the idea that obscurin/obsl1 
without proteasome inhibitors. In contrast, polyubiquitylated 
sAnk1.5 was only visible after inhibition of the UPS by MG132. The 
observed differences between polyubiquitylation and neddylation 
of sAnk1.5 indicate that neddylation either serves an unrecognized 
function, or that nedd8 competitively occupies lysine residues 
needed for ubiquitylation.
FIGURE 7: Analysis of sAnk1.5, KCTD6, cullin-3, and RhoA expression 
level and localization in obscurin knockout muscle. (A) Knockout of 
obscurin leads to changes in sAnk1.5, RhoA, KCTD6, and cullin-3 
protein localization. Frozen sections of wild-type and obscurin 
knockout cross-striated muscle tissues were stained with antibodies 
directed against sAnk1.5, KCTD6, RhoA, and cullin-3. Prominent 
M-band localization of sAnk1.5, KCTD6, and RhoA in wild-type muscles 
appears abrogated in muscles from obscurin knockout animals. 
sAnk1.5 and RhoA are either diffuse or weakly associated to sarcomeric 
Z-disks in obscurin knockout muscles, whereas KCTD6 displays 
prominent Z-disk and intercalated disk association. Intriguingly, 
prominent localization of cullin-3 to sarcomeric Z-disks remains 
unchanged. Myomesin, titin-M8, and α-actinin were used as sarcomeric 
counterstains to show localization of sarcomeric M-band and Z-discs, 
respectively. Note that the sAnk1.5 staining for obscurin knockout 
muscles was recorded at higher gain settings compared with the 
wild-type muscle tissue to emphasize changes to sAnk1.5 localization. 
Indeed, sAnk1.5 levels were significantly decreased in obscurin 
knockout muscles (Lange et al., 2009). Scale bar: 10 μm. (B) KCTD6 and 
cullin-3 localize to the intercalated disk in frozen sections of obscurin 
cardiac muscle. Cross-sections of muscle from wild-type and obscurin 
knockout hearts were stained with antibodies raised against KCTD6 
and cullin-3 (red in overlay). Plakoglobin (γ-catenin) staining was used as 
intercalated disk (ID) marker (blue in overlay); F-actin was used to 
display sarcomeres (green in overlay). Scale bar: 6 μm.
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of UNC-89 with MEL-26, a BTB/POZ-domain protein similar 
to KCTD6 that also interacts with cullin-3 (Wilson et al., 2012). 
Whether obscurin and/or Obsl1 exert a regulatory function on 
may directly and/or indirectly associate with and putatively regu-
late cullin-dependent protein turnover (Figure 8C). Moreover, 
Guy Benian and colleagues recently found a direct interaction 
FIGURE 8: Summary of known and novel obscurin–sAnk1.5 protein interactions and posttranslational modifications. 
Changes to proteins in obscurin knockouts and a possible link to hereditary spherocytosis. (A) Summary of novel and 
known protein interactions. Domain structure of obscurin C-terminus, sAnk1.5, KCTD6, and cullin-3 and mapped 
minimal binding sites are indicated. Amino acid residues are for human sAnk1.5, KCTD6, and cullin-3. OBD, obscurin 
binding domain; ABD, ankyrin binding domain; TM, transmembrane domain; Obsc, obscurin. Posttranslational 
modification of sAnk1.5 by nedd8, ubiquitin, and acetylation of lysine residues is indicated. (B) Summary of sAnk1.5 
(Ank), KCTD6, RhoA, and cullin protein localization changes between wild-type (left panel) and obscurin knockout heart 
muscles (right panel). ID, intercalated disk; M, M-band; Z, Z-disk; SR, sarcoplasmic reticulum. (C) Summary of obscurin 
domain layout and its protein interaction network, with novel and known protein interactions. Proteins involved in 
sarcomeric structure and protein turnover are grouped. (D) Mapping of KCTD6 site in sAnk1.5 reveals that the exon 
44 encoding for the bulk of the binding region is also found in erythrocyte splice variants of Ank1 (eAnk1). Novel and 
known disease-associated Ank1 mutations that lead to C-terminal truncation of the protein may abrogate putative 
binding of KCTD6 to ankyrin-1 in erythrocytes. This finding raises the possibility of an involvement of KCTD6 in the 
development of Ank1-linked hereditary spherocytosis. Domain structure not to scale. Ank, ankyrin repeats; SBD, 
spectrin binding domain; DD, death domain. (E) Expression of Ank1 and KCTD6 in whole blood (WB), purified red blood 
cells (RBC), or blood plasma (Pl). The giant ankyrin-1 splice isoforms were detected in whole blood or purified red blood 
cells. A KCTD6 immunoreactive band at 30 kDa and approximately 25 kDa was detected in purified red blood cells. 
(F) KCTD6 partially colocalizes in red blood cells with ankyrin-1. Scale bar: 10 μm.
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Generation of sAnk1.5, KCTD6, obscurin, Nedd8, ubiquitin, 
sumo1, and cullin-3 constructs for expression in eukaryotic cells, 
was done by PCR from a human cardiac cDNA library (Clontech, 
Mountain View, CA), and subcloning into the pEGFP-C1, pHA-N1, 
pHA-C1, and the protein complementation split–YFP vectors (Zou 
et al., 2006) YN-C1, YC-N1, and YC-C1. The pHA-N1/C1 vectors 
were produced by in-frame replacement of the EGFP coding se-
quence in the pEGFP-N1/C1 vectors (Clontech) with the hemag-
glutinin (HA) tag (YPYDVPDYA). The construct for expression of 
sAnk1.5 in bacteria was done by in-frame integration of the cyto-
plasmic part of sAnk1.5 (residues 29–155) into pGST-C1, a modi-
fied pGEX-2TK vector, in which the multiple cloning site has been 
replaced with the multiple cloning site of the pEGFP-C1 vector. 
Generation of the construct for bacterial expression of His-tagged 
KCTD6 was done by subcloning human KCTD6 into the pTev vec-
tor (Pinotsis et al., 2007), a modified version of the pET22b(+) vec-
tor (Novagen; Merck KGaA, Darmstadt, Germany), via PCR. The 
rat KCTD6 RNAi constructs were done by linker ligation of the fol-
lowing oligonucleotides (see Supplemental Table S1), into the H1-
GFP vector (Fukuzawa et al., 2008), a modified version of the pSU-
PER vector (kind gift of R. Agami, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands; Brummelkamp et al., 2002).
Site-directed mutagenesis of sAnk1.5 and KCTD6 constructs was 
done using a modified version of the QuickChange mutagenesis 
protocol (Stratagene, Agilent, Santa Clara, CA) and oligonucleotides 
harboring the desired mutation (Fukuzawa et al., 2008).
All cDNAs and mutations were verified by sequencing. All resi-
due numbers correspond to human sAnk1.5 (Homo sapiens ankyrin 
1, transcript variant 5; National Center for Biotechnology Informa-
tion [NCBI] accession number: NM_020478), human KCTD6 (NCBI 
accession number: NM_153331), and human cullin-3 (NCBI acces-
sion number: NM_003590).
Yeast two-hybrid assay
A yeast two-hybrid assay was done as previously described (Lange 
et al. 2002). pLexA-sAnk1.5 (29–155) was cotransformed with a 
pGAD10 human cardiac muscle cDNA library (Clontech) into the 
L40 yeast strain. Transformants were screened by HIS3 and LacZ 
reporter gene activity. For forced yeast two-hybrid assays, pLexA-
sAnk1.5 (residues 29–155, 29–137, 29–99, or 29–63) were cotrans-
formed with either empty pACT2 vector or pACT2-KCTD6 (residues 
1–147). After selection and growth of positive yeast transformants 
on minimal SD-medium lacking amino acids leucine and tryptophan, 
positive interaction was analyzed by LacZ reporter gene activity in 
an Xgal filter assay.
Cell culture
Cos-1 cells (Gluzman, 1981), C2C12 cells (Yaffe and Saxel, 1977), 
and NRCs were cultured as described previously (Lange et al., 
2002). NRC and Cos-1 cells at 80% confluency were transfected us-
ing ESCORT III (Sigma-Aldrich, St. Louis, MO) or Lipofectamine-2000 
(Invitrogen, Life Technologies, Carlsbad, CA) following the manu-
facturers’ manuals, and were harvested for immunofluorescence, 
coimmunoprecipitation, and/or immunoblot analysis 48 h after 
transfection. C2C12 cells in the myoblast stage were transfected 
using Lipofectamine-2000. C2C12 cells were changed from growth 
medium (20% FCS, DMEM, 1× penicillin/streptomycin) into differ-
entiation medium (2% horse serum, DMEM, 1× penicillin/strepto-
mycin) 24 h after transfection, and then differentiated for 1–12 d.
KCTD6 RNAi was done by transfection of a rat-specific KCTD6 
H1-GFP vector by using ESCORT III into NRC. The effect of small 
interfering RNA (siRNA) was assessed 5 d after transfection.
cullin-dependent protein turnover, a scaffolding function, or 
an as yet unidentified role for cullin remains to be characterized.
Another striking feature of obscurin knockout muscle is the dif-
fuse localization of RhoA. While RhoA was recently characterized as 
a cullin-3 substrate through interaction with KCTD13 (Chen et al., 
2009), unaltered protein levels of RhoA in knockout muscles reason 
against an involvement of this pathway as a primary cause for the 
mislocalization of RhoA. Loss of RhoA binding to the SH3-DH-PH 
domains in obscurin (Ford-Speelman et al., 2009) is the likely expla-
nation for the drastically altered RhoA localization. Intriguingly, no 
physiological effects or myofibrillar defects (Lange et al., 2009) were 
found associated with diffuse RhoA localization, rendering the as-
sociation of RhoA with obscurin, its localization at the M-band, and 
its role in muscle biology more obscure.
During the identification of the minimal binding site of KCTD6 in 
human sAnk1.5, we noticed that exon 44a encompassing the region 
of ankyrin OBD-2 was also included in erythrocyte variants of human 
ANK1 (Figure 8D). Intriguingly, several known mutations affecting the 
giant erythrocyte ankyrin-1 isoforms may directly or indirectly impact 
the KCTD6 minimal binding site (del Giudice et al., 1996; Eber et al., 
1996; Hughes et al., 2011; Figure 8D, human single-nucleotide poly-
morphisms), mostly through premature termination and truncation of 
the ankyrin C-terminus. Particularly, the probably pathogenic poly-
morphism rs137852831 located at the extreme C-terminus of the 
regulatory domain of erythrocyte ANK1 leads to a truncation in the 
KCTD6 binding site (R1833X in human ANK1 isoform 3). Other nu-
cleotide polymorphisms with unknown clinical relevance that are lo-
cated within the mapped binding site of KCTD6 are rs143987736 
and rs145506191, which result in the following mutations in ANK1 
isoform 3: D1841N and A1843T, respectively. The expression of the 
KCTD6 binding site in erythrocyte ANK1 and the unknown disease 
mechanism of ankyrin-1 truncations in hereditary spherocytosis raise 
the possibility that KCTD6 may also interact with ankyrin-1 in eryth-
rocytes and could be involved in the disease etiology. Indeed, KCTD6 
is expressed in purified erythrocytes (Figure 8E), and colocalizes with 
ankyrin-1 along the red blood cell membrane (Figure 8F). Moreover, 
hereditary spherocytosis involving ANK1 gene mutations may be as-
sociated with altered levels of ankyrin binding partners spectrin and 
band-3 and associated proteins (Hughes et al., 2011; Peker et al., 
2011). We speculate that pathological ANK1 mutations may be 
linked with the KCTD6/cullin-3 mediated ankyrin turnover mecha-
nism described here. Ankyrin mutations may impair the ankyrin/
KCTD6 interaction, resulting in altered stability of ankyrin-1 and its 
binding partners during erythrocyte development, leading to an im-
pairment of the erythrocyte membrane cytoskeleton and ultimately, 
deformed red blood cells, as present in hereditary spherocytosis. It 
would be fascinating to investigate whether patients that suffer from 
hereditary spherocytosis and exhibit truncation of ankyrin-1 show 
concomitant changes in KCTD6 and cullin-3, as well as altered pro-
tein turnover in erythrocytes. Moreover, existence of patients that 
exhibit hereditary spherocytosis and symptoms of skeletal muscle 
myopathy (McCann and Jacob, 1976; Spencer et al., 1987) and/or 
cardiomyopathy (Moiseyev et al., 1987; Alter and Maisch, 2007; 
Finsterer and Stollberger, 2007) hint at a common molecular mal-
function, potentially involving ankyrin-1 and KCTD6/cullin-3.
MATERIALS AND METHODS
Generation of constructs
KCTD6 and the cytoplasmic part of sAnk1.5 (residues 29–155) used 
for the yeast two-hybrid screen and the forced yeast two-hybrid as-
say were either cloned into pACT2 or pLexA vectors (Fukuzawa 
et al., 2008) via PCR.
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WA). Significance was determined using analysis of variance calcula-
tion with a significance level of 0.05 or 0.01. Results are presented 
as means ± SE. Number of measurements (n) and p values are shown 
in the figures or legends.
Antibodies
Antibodies raised against human KCTD6 were obtained from 
Abcam (Cambridge, MA; ab62596). Polyclonal mouse anti-KCTD6 
antibodies were generated in-house by intramuscular injection of a 
1:1 mixture of 2 mg His-tagged human KCTD6-BTB domain and 
TiterMax Gold adjuvant (Sigma-Aldrich) into mice. Three months 
following the injection, mouse serum was collected and tested for 
immunoreactivity. Antibodies raised against sAnk1.5 were obtained 
from Aviva Sysbio (ARP42566_T100). Antibodies raised against GFP 
and HA tags were obtained from Roche (Indianapolis, IN). The anti-
body recognizing an obscurin epitope in domains IQ-Ig64 was gen-
erated in our laboratory (Lange et al., 2009). Additionally, the follow-
ing mouse, goat, and rabbit antibodies were used in this study: 
myomesin-B4 (Developmental Studies Hybridoma Bank [DSHB] 
University of Iowa, developed by J. C. Perriard, ETH Zurich, Zurich, 
Switzerland), α-actinin (clone EA53; Sigma-Aldrich), titin-M8 
(developed by Mathias Gautel, King’s College London, United 
Kingdom), nedd8 (Sigma-Aldrich), cullin-3 (Sigma-Aldrich), Skp1 
(Santa Cruz Biotechnology), CSN5 (Santa Cruz Biotechnology), 
MyHC (clone 1025; DSHB University of Iowa, developed by H. Blau, 
Stanford University, Stanford, CA), RhoA (Santa Cruz Biotechnol-
ogy), p62 (BD-Transduction, San Jose, CA), GAPDH (Santa Cruz 
Biotechnology), β-tubulin (clone E7; DSHB University of Iowa, devel-
oped by M. Klymkowsky, University of Colorado, Boulder, CO), 
plakoglobin (BD-Transduction), and acetyl-lysine (Cell Signaling 
Technology). All fluorescently or enzymatically (horseradish peroxi-
dase) labeled secondary antibodies were from either Dako or 
Jackson ImmunoResearch (West Grove, PA).
For immunofluorescence, 4′,6-diamidino-2-phenylindole (DAPI; 
2 mg/ml; Sigma-Aldrich) or fluorescently labeled phalloidin (Mole-
cular Probes) was incubated with the secondary antibody mixture.
Coimmunoprecipitation and GST-pulldown assays
Biochemical protein–protein interaction assays were performed as 
described previously (Lange et al., 2002). Bacterial expression was 
done in BL21 Star cells (Invitrogen) following standard procedures 
(Lange et al., 2002). For GST-pulldown assays, purified GST-tagged 
sAnk1.5 (residues 29–155) in IP buffer (150 mM NaCl, Tris-HCl pH 8, 
1 mM DTT, 1× Complete Protease Inhibitor EDTA-free [Roche], 0.2% 
NP-40) was bound to glutathione Sepharose 4B resin (Pharmacia). 
For coimmunoprecipitations, soluble immunocomplexes in IP buffer 
were bound to protein G–linked magnetic beads (Dynabeads; 
Invitrogen). Following binding of the protein–protein complexes or 
protein–immunocomplexes and incubation at 4°C for 2 h with agita-
tion, beads were washed three times with IP buffer, resuspended in 
SDS sample buffer, and analyzed by SDS–PAGE, which was followed 
by immunoblotting onto nitrocellulose membranes (Schleicher & 
Schuell or Bio-Rad, Hercules, CA).
Protein analysis and cross-linking
To generate protein samples from transfected or untransfected Cos-
1, C2C12, or NRC, cells were washed once in PBS and directly lysed 
in SDS-sample buffer. Mouse tissue samples were homogenized di-
rectly in SDS sample buffer (1:40 tissue weight [mg]:SDS-sample 
buffer volume [ml] ratio) using a polytron-blade homogenizer (Pro 
Scientific). Protein levels were equalized by adjusting protein 
amounts according to actin, β-tubulin, or GAPDH intensity.
Treatment of cells with HDAC inhibitor was done by supplement-
ing the growth medium with 0.5 μg/ml TSA (Sigma-Aldrich) for 
4–24 h. Investigation of protein degradation was done by supple-
menting cell culture medium with either 10 μM MG132 (Santa Cruz 
Biotechnology, Santa, Cruz, CA) and culturing cells for 3–24 h, or 
with 10 μg/ml cycloheximide (CHX; Santa Cruz Biotechnology) and 
culturing cells for 6 h. For analysis of protein phosphorylation, cells 
were incubated with 200 nM staurosporine (Sigma-Aldrich) in cell 
culture medium for 1 h.
Immunostaining and microscopy
Immunostaining of frozen sections and cells was done as previously 
described (Lange et al., 2002). Immunostaining of frozen cardiac sec-
tions was done by fixing cross-sections (10 μm) in ice-cold acetone 
for 5 min at −20°C, which was followed by rehydration in 1X phos-
phate-buffered saline (PBS) for 5 min at room temperature. After 
permeabilization (0.2% Triton X-100 for 5 min at room temperature), 
sections were incubated with a mixture of primary antibodies in 
gold buffer (GB; 20 mM Tris-HCl, pH 7.5, 155 mM NaCl, 2 mM eth-
ylene glycol tetraacetic acid, 2 mM MgCl2, 5% bovine serum albu-
min [BSA]) overnight at 4°C. After being washed with PBS, the sec-
tions were transferred into the secondary antibody mixture (in GB), 
incubated for 1 h at room temperature, washed again with PBS, and 
finally mounted in fluorescent mounting medium (Dako, Carpinteria, 
CA). Immunostaining of Cos-1, C2C12, NRC, and diaphragm whole 
mounts was done using a similar protocol, but the acetone fixation 
step was replaced with a 4% PFA/PBS fixation for 5–15 min at room 
temperature. Immunostaining of red blood cells was performed af-
ter isolation and purification of intact erythrocytes from whole blood 
by centrifugation at 1000 × g in a tabletop centrifuge for 1 min, 
transfer of the red blood cell fraction to a new tube, and washing of 
erythrocytes with PBS. Fixation of erythrocytes was done by resus-
pending and incubating red blood cells in 2% glutaraldehyde, 2% 
PFA in 0.15M cacodylate buffer (pH 7.4) for 10 min at room tempera-
ture. After fixation, red blood cells were permeabilized for 5 min with 
0.1% triton in PBS and stained in suspension with primary antibodies 
diluted in PBS supplemented with 1% BSA for 2 h at room tempera-
ture, which was followed by three washes using PBS and labeling 
with secondary antibodies diluted in PBS with 1% BSA. Cells were 
washed three times with PBS and mounted on coverslips in PBS for 
confocal microscopy. Samples were imaged using an Olympus Flu-
oview confocal microscope in sequential scanning mode using 40× 
or 60× oil-immersion objectives and zoom rates between 1 and 4.
Sequence analysis, image analysis, and statistical analysis
Secondary-structure analysis was done using the Web-based pre-
diction software JPRED3 (University of Dundee, United Kingdom; 
www.compbio.dundee.ac.uk/∼www-jpred). Prediction of putative 
phosphorylation sites was done using NetPhos (Blom et al., 1999; 
www.cbs.dtu.dk/services/NetPhos) or phosphosite (Cell Signaling 
Technology, Danvers, MA; www.phosphosite.org). Domain predic-
tion was done using SMART (Schultz et al., 1998; European Molecu-
lar Biology Laboratory; http://smart.embl-heidelberg.de). Helical 
wheel projections were done using a Web-based software created 
by Don Armstrong (http://rzlab.ucr.edu/scripts/wheel/wheel.cgi).
Densitometric analysis of immunoblots and ratiometric analysis 
of fluorescent images was done using ImageJ (National Institutes of 
Health [NIH]). For visualization of protein levels in NRCs transfected 
with RNAi constructs, look-up tables in channels depicting KCTD6 
or sAnk1.5 were changed in ImageJ to 16 colors (16_colors.lut; 
shown in the intensity scale in Figure 6 and Supplemental Figure 
S6A). Statistical analysis was done using Excel (Microsoft, Redmond, 
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For mobility shift assays, HA-tagged sAnk1.5 or KCTD6 was 
transfected with or without GFP-tagged nedd8 or sumo-1. At 48 h 
after transfection, proteins were harvested directly in SDS-sample 
buffer and analyzed on SDS–PAGE; this was followed by immunob-
lot analysis.
For treatment of proteins with shrimp alkaline phosphatase (SAP), 
transfected cells were washed once in PBS and lysed in IP buffer. 
After separation of the soluble and insoluble fraction by centrifuga-
tion at 14,000 rpm in a tabletop centrifuge at 4°C, soluble proteins 
were incubated with 26 U/ml of SAP (Roche) for 45 min at 37°C. 
After proteins were mixed with SDS-sample buffer, they were sepa-
rated on SDS–PAGE; this was followed by immunoblot analysis.
Chemical cross-linking of protein lysates from transfected Cos-1 
cells was done as described previously (Lange et al., 2005a). Lysates 
from transfected Cos-1 cells containing soluble fractions of HA-
tagged full-length KCTD6 or KCTD6 N-terminal BTB domain were 
changed from IP buffer (see Coimmunoprecipitation and GST- 
pulldown assays section) into PBS using Zeba Spin columns (Pierce, 
Rockford, IL). After addition of chemical cross-linker ethylene glycol 
bis(succinimido succinate); Sigma-Aldrich) to a final concentration of 
1.3 mM and incubation of protein samples at 37°C for 15 min, pro-
teins were precipitated by adding 12% trichloroacetic acid (1:1 ratio). 
Proteins were pelleted for 10 min at 4°C using a tabletop microcentri-
fuge, and the protein pellet was redissolved in SDS sample buffer and 
separated by SDS–PAGE; this was followed by immunoblot analysis.
Mice
Generation of obscurin knockout mice has been described previ-
ously (Lange et al., 2009). All procedures involving mice were done 
in accordance with the Institutional Animal Care and Use Commit-
tee, NIH, and Association for Assessment and Accreditation of Lab-
oratory Animal Care regulations under the observance and care of 
trained animal staff and veterinarians.
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